A Phase 3 interventional study of SEP-363856 50mg and SEP-363856 75mg in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 53 sites in 6 countries. Open to participants aged 13 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.
Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 3rd largest by enrollment, is one of 5 that started in 2019, is one of 9 in phase 3, and was the 7th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 13 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 3 · Phase 3 10
First in 2013; this study’s year is marked. 5 started in 2019.
This study's enrollment of 463 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 83 across the 23 interventional studies. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 23 have an industry lead sponsor. The 3 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 19th largest by enrollment of the 111 interventional ones that give a count, is one of 13 that started in 2019, is one of 50 in phase 3, and was the 96th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing SEP-363856 in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo. This study is accepting male and female participants between 13 years old -65 years old who have been diagnosed with schizophrenia.
This is a multicenter, randomized, double-blind, parallel-group, fixed-dosed study evaluating the efficacy and safety of two doses of SEP-363856 (50 and 75 mg/day) versus placebo over a 6-week Treatment Period in acutely psychotic subjects with schizophrenia. This study is projected to randomize approximately 435 subjects (18-65 years) to 3 treatment groups (SEP-363856 50 mg/day, SEP-363856 75 mg/day, or placebo) in a 1:1:1 ratio. In addition, the study will randomize approximately 90 adolescent subjects (13-17 years) in a 1:1:1 ratio to the 3 treatment groups (with approximately 30 subjects per group) in a separate cohort. Treatment assignment will be stratified by country. Study drug will be taken once a day and may be taken with or without food.
This study is designed to test the hypothesis that, treatment with SEP-363856 in adult subjects with schizophrenia will result in significantly greater reduction (i.e. improvement) in PANSS total score and CGI-S score at Week 6 from Baseline when compared to placebo. The overall Type I error is controlled for two hierarchical families of hypotheses. The first family includes hypotheses about the testing of change from Baseline in PANSS total score at Week 6 between each of the SEP-363856 dose levels vs. placebo. The second family of hypotheses are about the testing of change from Baseline in CGI-S score at Week 6 between each of the SEP-363856 dose levels vs. placebo.
Sumitomo Pharma America Inc. was the former Sponsor and conducted this study. Sumitomo was responsible for analysis and clinical study report (CSR) completion. Otsuka took over study after IND was transferred and is concluding activities with registry postings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SEP-363856 50mg dosed once daily
Drug: SEP-363856 50mg
SEP-363856 75mg dosed once daily
Drug: SEP-363856 75mg
Placebo dosed once daily
Drug: Placebo
SEP-363856 50mg tablet dosed once daily
SEP-363856 75mg tablet dosed once daily
Placebo tablet dosed once daily
Change From Baseline in PANSS Total Score at Week 6
PANSS was an interview-based assessment comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). The Positive subscale assessed hallucinations, delusions, and related symptoms; the Negative subscale assessed emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addressed other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 - 7, where values of 2 and above indicated the presence of progressively more severe symptoms, was used to score each item. Individual items were then summed to determine scores for the 3 subscales, as well as a total score. PANSS total score ranges from: 30-210, where a higher score indicates greater severity. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 6
Change From Baseline in CGI-S Total Score at Week 6
The CGI-S was a single-item clinician-rated assessment of the participant's current illness state on a 7-point scale (score range: 1-7), where a higher score was associated with greater illness severity.
Time frame: Baseline, Week 6
Participants took part in the study at investigational sites in the United States, Russia, Ukraine, Bulgaria, and Serbia from 17 September 2019 to 12 September 2023.
| Milestone | Adults: Placebo | Adults: SEP-363856 50mg | Adults: SEP-363856 75mg | Adolescents: Placebo | Adolescents: SEP-363856 50mg | Adolescents: SEP-363856 75 mg |
|---|---|---|---|---|---|---|
| Started | 146 | 144 | 145 | 10 | 9 | 9 |
| Completed | 119 | 110 | 118 | 10 | 8 | 8 |
| Not completed | 27 | 34 | 27 | 0 | 1 | 1 |
| Withdrew: Adverse event | 6 | 18 | 11 | 0 | 0 | 0 |
| Withdrew: Covid-19 related adverse event | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 4 | 5 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 13 | 10 | 10 | 0 | 0 | 1 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 related | 0 | 1 | 1 | 0 | 0 | 0 |
PANSS was an interview-based assessment comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). The Positive subscale assessed hallucinations, delusions, and related symptoms; the Negative subscale assessed emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addressed other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 - 7, where values of 2 and above indicated the presence of progressively more severe symptoms, was used to score each item. Individual items were then summed to determine scores for the 3 subscales, as well as a total score. PANSS total score ranges from: 30-210, where a higher score indicates greater severity. A negative change from baseline indicates improvement.
| score on a scale | Adults: Placebo | Adults: SEP-363856 50mg | Adults: SEP-363856 75mg |
|---|---|---|---|
| Change From Baseline in PANSS Total Score at Week 6 | -19.3 ± 1.55 | -16.9 ± 1.57 | -19.6 ± 1.56 |
The CGI-S was a single-item clinician-rated assessment of the participant's current illness state on a 7-point scale (score range: 1-7), where a higher score was associated with greater illness severity.
| score on a scale | Adults: Placebo | Adults: SEP-363856 50mg | Adults: SEP-363856 75mg |
|---|---|---|---|
| Change From Baseline in CGI-S Total Score at Week 6 | -0.90 ± 0.085 | -0.80 ± 0.086 | -1.01 ± 0.086 |
Collected over From the first dose of study drug up to 7 days after the last dose of the study drug (up to approximately 7 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adults: Placebo | 0/146 (0%) | 4/146 (2.7%) | 41/146 (28.1%) |
| Adults: SEP-363856 50mg | 0/144 (0%) | 11/144 (7.6%) | 55/144 (38.2%) |
| Adults: SEP-363856 75mg | 0/145 (0%) | 12/145 (8.3%) | 50/145 (34.5%) |
| Adolescents: Placebo | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Adolescents: SEP-363856 50mg | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| Adolescents: SEP-363856 75mg | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Event | Adults: Placebo | Adults: SEP-363856 50mg | Adults: SEP-363856 75mg | Adolescents: Placebo | Adolescents: SEP-363856 50mg | Adolescents: SEP-363856 75mg |
|---|---|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 3/146 | 10/144 | 12/145 | 0/10 | 0/9 | 0/9 |
| Drug ineffectiveGeneral disorders | 0/146 | 1/144 | 0/145 | 0/10 | 0/9 | 0/9 |
| Nerve injuryInjury, poisoning and procedural complications | 0/146 | 0/144 | 1/145 | 0/10 | 0/9 | 0/9 |
| Tendon injuryInjury, poisoning and procedural complications | 0/146 | 0/144 | 1/145 | 0/10 | 0/9 | 0/9 |
| Generalised tonic-clonic seizureNervous system disorders | 0/146 | 0/144 | 1/145 | 0/10 | 0/9 | 0/9 |
| Corona virus infectionInfections and infestations | 1/146 | 0/144 | 0/145 | 0/10 | 0/9 | 0/9 |
| Event | Adults: Placebo | Adults: SEP-363856 50mg | Adults: SEP-363856 75mg | Adolescents: Placebo | Adolescents: SEP-363856 50mg | Adolescents: SEP-363856 75mg |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 9/146 | 17/144 | 17/145 | 1/10 | 2/9 | 2/9 |
| NauseaGastrointestinal disorders | 11/146 | 12/144 | 10/145 | 0/10 | 2/9 | 1/9 |
| SchizophreniaPsychiatric disorders | 4/146 | 16/144 | 13/145 | 0/10 | 1/9 | 1/9 |
| Abnormal dreamsPsychiatric disorders | 0/146 | 0/144 | 0/145 | 0/10 | 0/9 | 1/9 |
| AgitationPsychiatric disorders | 7/146 | 8/144 | 11/145 | 0/10 | 0/9 | 1/9 |
| DizzinessNervous system disorders | 0/146 | 0/144 | 0/145 | 0/10 | 0/9 | 1/9 |
| SomnolenceNervous system disorders | 0/146 | 0/144 | 0/145 | 0/10 | 0/9 | 1/9 |
| Abdominal painGastrointestinal disorders | 0/146 | 0/144 | 0/145 | 0/10 | 0/9 | 1/9 |
| Abdominal pain upperGastrointestinal disorders | 0/146 | 0/144 | 0/145 | 0/10 | 0/9 | 1/9 |
| Dry mouthGastrointestinal disorders | 0/146 | 0/144 | 0/145 | 0/10 | 0/9 | 1/9 |
Safety population included all randomized participants that received at least one dose of study drug.
| Age, Continuous(years) | Adults: Placebo | Adults: SEP-363856 50mg | Adults: SEP-363856 75mg | Adolescents: Placebo | Adolescents: SEP-363856 50mg | Adolescents: SEP-363856 75mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 35.7 ± 10.33 | 36.1 ± 9.38 | 37.0 ± 10.23 | 15.5 ± 1.43 | 14.8 ± 1.39 | 15.0 ± 1.41 | 35.0 ± 10.92 |
| Sex: Female, Male(Participants) | Adults: Placebo | Adults: SEP-363856 50mg | Adults: SEP-363856 75mg | Adolescents: Placebo | Adolescents: SEP-363856 50mg | Adolescents: SEP-363856 75mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 73 | 46 | 59 | 4 | 5 | 3 | 190 |
| Male | 73 | 98 | 86 | 6 | 4 | 6 | 273 |
| Ethnicity (NIH/OMB)(Participants) | Adults: Placebo | Adults: SEP-363856 50mg | Adults: SEP-363856 75mg | Adolescents: Placebo | Adolescents: SEP-363856 50mg | Adolescents: SEP-363856 75mg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 3 | 0 | 1 | 0 | 12 |
| Not Hispanic or Latino | 143 | 139 | 142 | 10 | 8 | 9 | 451 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Adults: Placebo | Adults: SEP-363856 50mg | Adults: SEP-363856 75mg | Adolescents: Placebo | Adolescents: SEP-363856 50mg | Adolescents: SEP-363856 75mg | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 2 | 1 | 0 | 1 | 0 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 30 | 30 | 33 | 5 | 5 | 6 | 109 |
| White | 114 | 113 | 111 | 3 | 3 | 2 | 346 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Region of Enrollment(participants) | Adults: Placebo | Adults: SEP-363856 50mg | Adults: SEP-363856 75mg | Adolescents: Placebo | Adolescents: SEP-363856 50mg | Adolescents: SEP-363856 75mg | Total |
|---|---|---|---|---|---|---|---|
| United States | 40 | 40 | 39 | 7 | 7 | 7 | 140 |
| Ukraine | 26 | 26 | 26 | 0 | 0 | 0 | 78 |
| Bulgaria | 18 | 18 | 18 | 0 | 0 | 0 | 54 |
| Serbia | 43 | 42 | 44 | 3 | 2 | 2 | 136 |
| Russia | 19 | 18 | 18 | 0 | 0 | 0 | 55 |
| PANSS Total Score(units on a scale) | Adults: Placebo | Adults: SEP-363856 50mg | Adults: SEP-363856 75mg | Adolescents: Placebo | Adolescents: SEP-363856 50mg | Adolescents: SEP-363856 75mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 101.9 ± 10.56 | 102.3 ± 10.02 | 101.7 ± 10.09 | 96.0 ± 10.51 | 104.6 ± 14.57 | 97.9 ± 8.16 | 101.8 ± 10.29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Sep 2019 to primary completion in May 2023, 43 months.
Results were first posted in May 2026, 3 years after primary completion. A results delay was requested in May 2024.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 43 months is above that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc. →